Hanif Razia, Mansoor Samina
Department of Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore.
J Coll Physicians Surg Pak. 2014 Mar;24(3):186-9.
To evaluate the diagnostic utility of Hep par-1 in differentiating hepatocellular carcinoma from metastatic carcinoma taking histopathology as a gold standard.
Comparative cross-sectional study.
Pathology Department, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, from April 2007 to February 2008.
Hep par-1 immunohistochemical stain was performed on 60 cases of liver carcinoma, 30 cases each of metastatic and hepatocellular carcinoma. Information regarding patient age, gender, sign and symptoms, radiographic findings, histological grade of tumour, and expression of Hep par-1 on hepatocellular and metastatic carcinoma were recorded on proforma sheet. Sensitivity, specificity, positive and negative predictive values, and accuracy of Hep par-1 were calculated using the formulas.
Hep par-1 expression was noted in 25 out of 30 cases of hepatocellular carcinoma (83%). Out of 30 cases of metastatic carcinoma, only one case expressed staining in < 5% tumour cells and remaining 29 cases showed no reactivity. The age of the patients with hepatocellular carcinoma ranged from 40 to 76 years with a median age of 60.5 years and 40 - 75 years for metastatic carcinomas with a median age of 57.5 years.
Hep par-1 is a reliable immunohistochemical marker for cases of hepatocellular carcinoma (HCC). It can be used along with other markers in morphologically difficult cases when differential diagnosis lies between poorly differentiated HCC and metastatic carcinoma of liver.
以组织病理学为金标准,评估Hep par-1在鉴别肝细胞癌与转移癌中的诊断效用。
比较性横断面研究。
2007年4月至2008年2月,拉合尔绍卡特·汗姆纪念癌症医院及研究中心病理科。
对60例肝癌病例进行Hep par-1免疫组化染色,其中转移癌和肝细胞癌各30例。将患者年龄、性别、体征和症状、影像学检查结果、肿瘤组织学分级以及Hep par-1在肝细胞癌和转移癌中的表达情况记录在表格中。使用公式计算Hep par-1的敏感性、特异性、阳性和阴性预测值以及准确性。
30例肝细胞癌中有25例(83%)出现Hep par-1表达。30例转移癌中,仅1例在<5%的肿瘤细胞中出现染色,其余29例无反应。肝细胞癌患者年龄在40至76岁之间,中位年龄为60.5岁;转移癌患者年龄在40至75岁之间,中位年龄为57.5岁。
Hep par-1是肝细胞癌(HCC)病例的可靠免疫组化标志物。当形态学诊断困难,鉴别诊断在于低分化HCC和肝转移癌时,它可与其他标志物联合使用。